Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Lucchetta, Rosa Camila; Riveros, Bruno Salgado; Pontarolo, Roberto; Radominski, Rosana Bento; Otuki, Michel Fleith; Fernandez-Llimos, Fernando; Correr, Cassyano Januário.
Clinics (Sao Paulo)
; 72(5): 317-324, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28591345
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients
Diethylpropion and mazindol: An end to the discussion?
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction.
A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
Binding of mazindol and analogs to the human serotonin and dopamine transporters.
Re-evaluation of the metabolism and excretion of diethylpropion in non-sustained and sustained release formulations.
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.